Assessment of ER-α and ER-β expression levels in malicious tumors of the uterine corpus

Purpose: The purpose of this article is to present an assessment of the expression levels of estrogen receptors ER-alpha and ER-beta in malicious tumors of the uterine corpus.

Material and methods: Estrogen receptor expression levels were tested using semiquantitative immunohistochemical methods. Paraffin-embedded sections of tissue from the corpus of the uterus from 171 patients were used in the research.

Results: Analysis of the relation between ER-beta expression levels and the clinical grade of disease (based on FIGO classification) showed that these parameters are significantly related: p = 0.0099. There were no statistically significant relations between ER-alpha expression levels in tumors or clinical stages of tumors based on the FIGO criteria. The presence of high estrogen receptor beta expression levels is often accompanied by a low estrogen receptor alpha expression level and such arrangements allow the overt biological function of a dominant receptor.

Conclusion: The differences in tissue distribution of both estrogen receptors could indicate their different biological roles.

[1] Baranowski W.: "Zagrozenia nowotworowe narzadu plciowego w okresie menopauzalnym". In: Jakowicki J.A., Klimakterium "Hormonalna terapia zastepcza". Poradnik terapeutyczny BiFolium, 2001, 103.

[2] Dockerty M.B., Lovelady S.B., Foust G.T. Jr.： “Carcinoma of corpus uteri in young women". Am. J. Obstet. Gynecol., 1951, 61, 147.

[3] Woodruff J.D., Pickar J.H.: "Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone" Am. J. Obstet. Gynecol., 1994, 170, 1213.

[4] Roy D., Liher J.G.: "Estrogen DNA damage and mutations". Mutations Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1999, 424, 107.

[5] Service R.F.: "New role for estrogen in cancer". Science, 1998, 279, 1631.

[6] Cavalieri E.L: "Molecular origin of cancer: Catechol estrogen -3,4 quinones as endogenous tumor initiators". Proc. Natl. Acad. Sci. USA, 1997, 94, 10937.

[7] Zhu B.T, Conney A.H.: "Functional role of estrogen metabolism in target cells review and perspectives". Carcinogenesis, 1998, 19, 1.

[8] Monks T.J., Hanzlik R.P., Cohen G.M.: "Quinone chemistry and toxicity". Toxicol. Appl. Pharmacol., 1992, 112, 2.

[9] Beato M., Klug J.: "Steroid hormone receptors: an update". Hum Reprod., 2000, 6, 225.

[10] Spencer T.E., Jenster G., Burcin M.M.: "Steroid receptor coacllvator-1 is a histone acetyltransferase". Nature, 1997, 389, 194.

[11] Webb P., Lopez G.N., Uht R.M., Kushner P.J.: "Tamoxifen activation of the estrogen receptor/ AP-I pathway: potential origin for the cell specific estrogen like effects of antiestrogens". Mal Endocrinol., 1995, 9, 443.

[12] Peach B., Webb P., Kuiper G.: "Differential ligand activation of estrogen receptors ERa and ERP at APl sites". Science, 1997, 277, 1508.

[13] Kuiper G.G., Carlsson B., Grandien K: "Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors a and P"- Endocrinology, 1997, 138, 863.

[14] lwao K., Miyoshi Y., Egawa Ch.: "Quantitative analysis of estrogen receptor- a and p messenger RNA expression in breast carcinoma by real-time polymerase chain reaction". Am. Cancer Soc., 2000, 8, 1732.

[15] Johnston S.D., Liu X., Zuo F: "Estrogen - related receptor a 1 functionally binds as a monomer to extended half-site sequences including ones contained within estrogen-response elements" Mot. Endocrinol., 1997, 11, 342.

[16] Pffefer U., Fecarotta E., Castagnetta L.: "Alternative splicing of the estrogen receptor primary transcript normally occurs in estrogen receptor positive tissues and ce11 lines". J. Steroid Biochem., 1996, 56, 99.

[17] Rey J.M., Pu」ol P., Dechaud H.: "Expression of estrogen receptor-alfa splicing variants and estrogen receptor beta in endometrium of infertile patients". Mot. Hum. Reprod., 1998, 7, 641.

[18] Popiela A., Baranowski W., Slomczynska M., Panszczyk M., Gabrys M.: "Estimation of estrogen receptor alfa and beta izoform expression in endometrial cancer". Gynecol. Endocrinol., 2002, 16 (suppl. 1).

[19] Kern S.E.: "Progressive genetic abnormalities in human neoplasia". In: Mendelson J., Howley P.M., Israel M.A., Liotta LA "The molecular basis of cancer". W.B. Saunders Company, 2001, 41, 70.

[20] Popiela A.: "Stezenie 5-metylo-2'deoksycytydyny w genomyowym DNA a ekspresja wybranych receptorow steroidowych w stanach przedrakowych i rakach trzonu macicy". Praca hab山tacyjna w toku. Postgraduate research project (in press).